Alector ALEC 深 滬
等待開盤 10-22 09:30:00 美东时间
3.21
-0.100
-3.02%
華盛通- 最 高3.27
- 今 開3.22
- 成交量 439.80万股
- 最 低 3.09
- 昨 收 3.31
- 總市值 3.24亿
- 52周最高 6.14
- 市盈率 靜 --
- 換手率 4.35%
- 52周最低 0.87
- 委 比 -99.76%
- 總股本 1.01亿
- 歷史最高 43.32
- 量 比 3.29
- 振 幅 5.44%
- 歷史最低 0.87
- 每 手 1
- 風險率 1.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alector Discontinues Open-Label Extension For Latozinemab; Co To Reduce Workforce By About 49%
Alector Pipeline OutlookAlector remains focused on advancing a pipeline of programs designed to treat neurodegenerative diseases through mechanisms that remove toxic proteins, replace deficient proteins, and restore
今天 04:35
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
Alector's Phase 3 INFRONT-3 trial of latozinemab (AL001) for FTD-GRN did not meet the primary clinical endpoint but showed statistically significant effects on plasma progranulin levels. The trial's secondary and exploratory endpoints, however, did not demonstrate benefits for FTD-GRN. The open-label extension and continuation study for latozinemab have been discontinued. Alector continues to advance its pipeline targeting neurodegenerative disea...
10-21 20:05
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals
4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.
10-10 16:32
美股大行评级 | 星展银行上调百度评级至"买入"，目标价177美元；多家机构上调Guardant Health(GH)目标价最高至80美元
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12美元升至12.5美元；Oppenheimer：维持Immuneering"跑赢大市"评级，目标价从21美元升至30美元
09-26 09:45
BTIG Reiterates Buy on Alector, Maintains $5 Price Target
BTIG analyst Thomas Shrader reiterates Alector (NASDAQ: ALEC) with a Buy and maintains $5 price target.
09-25 19:53
Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs
Alector will host a virtual event on September 22, 2025, to discuss its PGRN franchise, including latozinemab (Phase 3 for GRN-related frontotemporal dementia) and AL101 (Phase 2 for early Alzheimer’s disease), as well as progress in its Alector Brain Carrier (ABC)-enabled programs. The event will feature preclinical data on new candidates for Alzheimer’s and Parkinson’s diseases, and updates on ABC-enabled siRNA programs. ABC aims to enhance the...
09-16 12:00
Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge
Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings.
09-08 17:59
Alector to Participate in Upcoming Healthcare Conferences
Alector, Inc. announced that its management will participate in three upcoming investor conferences in New York: the Cantor Global Healthcare Conference 2025 on September 4, the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9. Webcasts of the presentations will be available on Alector’s website, with replays accessible for 90 days. Alector focu...
08-28 12:00
Alector Raises FY2025 Sales Guidance from $5.000M-$15.000M to $13.000M-$18.000M vs $12.114M Est
Alector (NASDAQ:ALEC) raises FY2025 sales outlook from $5.000 million-$15.000 million to $13.000 million-$18.000 million vs $12.114 million estimate.
08-08 04:48
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
